-

EQUITY ALERT: Rosen Law Firm Encourages Ocugen, Inc. Investors with Losses to Inquire About Class Action Investigation – OCGN

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) resulting from allegations that Ocugen may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Ocugen securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to http://www.rosenlegal.com/cases-register-2107.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On May 26, 2021, Ocugen stated its plan to submit an Emergency Use Authorization (“EUA”) application for COVAXIN™, a COVID-19 vaccine, to the U.S. Food & Drug Administration (“FDA”) in June 2021.

Then on June 10, 2021, the Company issued a press release announcing that it “will no longer pursue an Emergency Use Authorization (EUA) for COVAXIN™” but would instead “pursue submission of a biologics license application (BLA) for its COVID-19 vaccine candidate, COVAXIN™.” The Company’s Chairman of the Board, CEO, and co-founder further revealed that “[a]lthough we were close to finalizing our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path[,]” and that “this will extend our timelines[.]”

On this news, Ocugen’s stock price fell sharply during intraday trading on June 10, 2021, damaging investors.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
cases@rosenlegal.com
pkim@rosenlegal.com
www.rosenlegal.com

Rosen Law Firm

NASDAQ:OCGN

Release Versions

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
cases@rosenlegal.com
pkim@rosenlegal.com
www.rosenlegal.com

More News From Rosen Law Firm

Rosen Law Firm Encourages Phreesia, Inc. Investors to Inquire About Securities Class Action Investigation – PHR

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Phreesia, Inc. (NYSE: PHR) resulting from allegations that Phreesia may have issued materially misleading business information to the investing public. So What: If you purchased Phreesia securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The R...

Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Propanc Biopharma Inc. (NASDAQ: PPCB) resulting from allegations that Propanc may have issued materially misleading business information to the investing public. So what: If you purchased Propanc securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme...

Rosen Law Firm Encourages Green Circle Decarbonize Technology Ltd. Investors to Inquire About Securities Class Action Investigation – GCDT

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Green Circle Decarbonize Technology Ltd. (NYSE American: GCDT) resulting from allegations that Green Circle may have issued materially misleading business information to the investing public. So what: If you purchased Green Circle securities you may be entitled to compensation without payment of any out of pocket fees or costs...
Back to Newsroom